Roflumilast, a phosphodiesterase-4 inhibitor, improves hyperoxia-induced lung injury via anti-inflammation.
RatOtherSprague-DawleyMaleOral2.5 mg/kg or 5 mg/kgOnce before hyperoxia exposure
Model: Hyperoxia-induced acute lung injury, pressurised to 250 kPa with pure oxygen
Roflumilast at both doses significantly reduced lung oedema, improved lung pathology and reduced inflammatory cytokine expression in the lung, with effects appearing dose related.
Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.